Table 1 Patient characteristics
Variables | Treatment naïve RA (n = 28) |
|---|---|
Age, median (IQR) years | 59.5 (47.5–67) |
Female, n (%) | 20 (71.4) |
Disease duration, median (IQR) months | 7 (3–24) |
RF positive, n (%) | 25 (89.2) |
ACPA positive, n (%) | 26 (92.9) |
Maximum dose of MTX, median (IQR) mg/week | 10 (8–11) |
Dose of prednisolone at baseline, median (IQR) mg/day | 0 (0–0) |
ESR, median (IQR) mm/h pre-treatment | 31 (14–46) |
ESR, median (IQR) mm/h post-treatment | 11 (9–27) |
CRP, median (IQR) mg/dl pre-treatment | 0.7 (0.3–1.5) |
CRP, median (IQR) mg/dl post-treatment | 0.1 (0.1–0.4) |
DAS28-ESR, median (IQR) pre-treatment | 4.21 (3.83–5.02) |
DAS28-ESR, median (IQR) post-treatment | 2.54 (2.02–4.39) |